Results 61 to 70 of about 52,343 (282)

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic

Journal of Clinical Medicine, 2020
Pharmacogenetic testing (PGT) is increasingly being used as a tool to guide clinical decisions. This article describes the development of an outpatient, pharmacist-led, pharmacogenetics consult clinic within internal medicine, its workflow, and early ...
Meghan J. Arwood, Eric A. Dietrich, Benjamin Q. Duong, D. M. Smith, Kelsey J Cook, Amanda L Elchynski, Eric I. Rosenberg, Katherine N. Huber, Ying Nagoshi, Ashleigh Wright, Jeffrey T. Budd, Neal P. Holland, Edlira Maska, Danielle K. Panna, Amanda R. Elsey, L. H. Cavallari, Kristin Wiisanen, Julie A. Johnson, J. Gums   +18 more
semanticscholar   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier, Kevin A. Friede, Mary E. Plomondon, Kyung Min Lee, Zhenyu Lu, Tia Dinatale, Scott L. DuVall, Jason L. Vassy, Stephen W. Waldo, John H. Cleator, Thomas M. Maddox, Daniel J. Rader, Themistocles L. Assimes, Scott M. Damrauer, Philip S. Tsao, Kyong‐Mi Chang, Deepak Voora, Julie A. Lynch, Jay Giri, VA Million Veteran Program, Sony Tuteja   +20 more
wiley   +1 more source

Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer

Nature Communications
Chemo-immunotherapy combinations have been regarded as one of the most practical ways to improve immunotherapy response in cancer patients. In this study, we integrate the transcriptomics data from anti-PD-1-treated tumors and compound-treated cancer ...
Yue Wang, Dhamotharan Pattarayan, Haozhe Huang, Yueshan Zhao, Sihan Li, Yifei Wang, Min Zhang, Song Li, Da Yang   +8 more
doaj   +1 more source

The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids

Cells, 2023
Connective tissue growth factor (CTGF) is involved in the regulation of extracellular matrix (ECM) production. Elevated levels of CTGF can be found in plasma from patients with liver fibrosis and in experimental animal models of liver fibrosis, but the ...
Sara Redenšek Trampuž, Sander van Riet, Åsa Nordling, Magnus Ingelman-Sundberg   +3 more
doaj   +1 more source

Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review

Pharmaceutics, 2020
Clinical research in high-income countries is increasingly demonstrating the cost- effectiveness of clinical pharmacogenetic (PGx) testing in reducing the incidence of adverse drug reactions and improving overall patient care.
Emiliene B Tata, Melvin A Ambele, Michael S Pepper   +2 more
semanticscholar   +1 more source

Impact of First‐of‐Its‐Kind Patient‐Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes

Clinical Pharmacology &Therapeutics, EarlyView.
Germline pharmacogenetics (PGx) is increasingly used to tailor medication selection/dosing. However, existing systems primarily communicate PGx results to providers, limiting direct patient engagement. To address this, we developed YourPGx Oncology, an innovative patient‐facing portal that delivers multi‐gene PGx results (CYP2D6, UGT1A1, DPYD) through ...
Youngwoo Cho, Sami Elahi, Matthew M. Jack, John Campbell, Emily Smith, Randall W. Knoebel, David George, Larry House, Kiang‐Teck J. Yeo, Theodore Karrison, Samuel L. Volchenboum, David O. Meltzer, Russell Z. Szmulewitz, Everett E. Vokes, Mark J. Ratain, Peter H. O'Donnell   +15 more
wiley   +1 more source

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

Expert Opinion on Drug Metabolism & Toxicology, 2018
Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some patients do not respond adequately or develop treatment related adverse events. This
Nihal El Rouby, J. Lima, Julie A. Johnson   +2 more
semanticscholar   +1 more source

Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings

Clinical and Translational Science, 2020
Most literature describing pharmacogenetic implementations are within academic medical centers and use single‐gene tests. Our objective was to describe the results and lessons learned from a multisite pharmacogenetic pilot that utilized panel‐based ...
D. M. Smith, B. Peshkin, T. Springfield, Ryan P. Brown, E. Hwang, Susanna Kmiecik, R. Shapiro, Z. Eldadah, Conor Lundergan, Joel McAlduff, Bonnie Levin, S. M. Swain   +11 more
semanticscholar   +1 more source

Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study

Clinical Pharmacology &Therapeutics, EarlyView.
The Ubiquitous Pharmacogenomics consortium (www.upgx.eu) has recently completed and published the Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE) study on the implementation of panel‐based pharmacogenetic testing. PREPARE has provided interesting lessons for the design, execution, and interpretation of future clinical
Henk‐Jan Guchelaar, Cathelijne H. van der Wouden, Lisanne E. N. Manson, Heshu Abdullah‐Koolmees, Kathrin Blagec, Tanja Blagus, Stefan Böhringer, Erika Cecchin, Ka‐Chun Cheung, Vera H. M. Deneer, Siv Jonsson, Candace Joefield‐Roka, Katja S. Just, Mats O. Karlsson, Lidija Konta, Rudolf Koopmann, Marjolein Kriek, Thorsten Lehr, Christina Mitropoulou, Victoria Rollinson, Rossana Roncato, Matthias Samwald, Elke Schaeffeler, Maria Skokou, Matthias Schwab, Daniela Steinberger, Julia C. Stingl, Roman Tremmel, Richard M. Turner, Mandy H. van Rhenen, Cristina L. Dávila‐Fajardo, Vita Dolžan, George P. Patrinos, Munir Pirmohamed, Gere Sunder‐Plassmann, Giuseppe Toffoli, Jesse J. Swen, Ubiquitous Pharmacogenomics Consortium   +37 more
wiley   +1 more source